Adverum Biotechnologies, Inc. (ADVM): Price and Financial Metrics
GET POWR RATINGS... FREE!
ADVM Stock Price Chart Interactive Chart >
ADVM Price/Volume Stats
|Current price||$0.76||52-week high||$1.82|
|Prev. close||$0.75||52-week low||$0.53|
|Day high||$0.76||Avg. volume||443,812|
|50-day MA||$0.71||Dividend yield||N/A|
|200-day MA||$0.94||Market Cap||75.56M|
Adverum Biotechnologies, Inc. (ADVM) Company Bio
Adverum Biotechnologies, Inc., a gene therapy company, engages in discovering and developing novel medicines that offer therapeutic benefit to patients suffering from chronic or debilitating disease. It primary focuses on developing AVA-101, which is in a Phase IIa trial for the treatment of wet age-related macular degeneration (AMD). The company was founded in 2006 and is based in Menlo Park, California.
Most Popular Stories View All
ADVM Latest News Stream
|Loading, please wait...|
ADVM Latest Social Stream
View Full ADVM Social Stream
Latest ADVM News From Around the Web
Below are the latest news stories about ADVERUM BIOTECHNOLOGIES INC that investors may wish to consider to help them evaluate ADVM as an investment opportunity.
Here's Why We're Watching Adverum Biotechnologies' (NASDAQ:ADVM) Cash Burn Situation
Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...
Adverum Biotechnologies to Present at Upcoming Investor Conferences
REDWOOD CITY, Calif., Feb. 27, 2023 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company that aims to establish gene therapy as a new standard of care for highly prevalent ocular diseases, today announced that Laurent Fischer, M.D., president and chief executive officer of Adverum Biotechnologies, will present at the following upcoming investor conferences: Cowen 43rd Annual Health Care Conference on Wednesday, March 8, 2023 at 12:50 p.m. ETOppenheimer 33rd
Adverum Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
REDWOOD CITY, Calif., Jan. 18, 2023 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company that aims to establish gene therapy as a new standard of care for highly prevalent ocular diseases, announced a grant of stock options to a new employee. On January 17, 2023, Adverum granted a new employee a stock option to purchase 150,000 shares of Adverum’s common stock pursuant to the inducement grant exception under Nasdaq Rule 5635(c)(4), as an inducement that is m
Adverum Biotechnologies Reports Third Quarter 2022 Financial Results
- First subject dosed in our Phase 2 LUNA trial with Ixo-vec (ixoberogene soroparvovec, formerly referred to as ADVM-022) and anticipate preliminary data throughout 2023 - Cash runway into 2025 prioritizing Ixo-vec clinical development in wet age-related macular degeneration (wet AMD) REDWOOD CITY, Calif., Nov. 10, 2022 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company that aims to establish gene therapy as a new standard of care for highly prevalent ocul
Adverum Biotechnologies Presents Positive End of Study Results from the OPTIC Trial in Wet AMD Including Two-Year Outcomes Following a Single Intravitreal Injection of Ixo-vec (ADVM-022)
- Data demonstrating that Ixo-vec was generally well tolerated and that a single intravitreal (IVT) injection can lead to stable and persistent aflibercept protein levels through three years in participants in the OPTIC extension study - 81% – 98% reduction in mean annualized anti-VEGF injections after a single IVT injection of Ixo-vec, including 80% and 53% of participants supplemental injection free over two years across the 6x10^11 (6E11) and 2x10^11 (2E11) doses, respectively, regardless of
ADVM Price Returns
Continue Researching ADVMHere are a few links from around the web to help you further your research on Adverum Biotechnologies Inc's stock as an investment opportunity:
Adverum Biotechnologies Inc (ADVM) Stock Price | Nasdaq
Adverum Biotechnologies Inc (ADVM) Stock Quote, History and News - Yahoo Finance
Adverum Biotechnologies Inc (ADVM) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...